Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when BNTC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsBenitec Biopharma engages Ernst & Young as independent auditor for fiscal 2027
Filed September 30, 2026 · Period ending September 29, 2026 · ~1 min read
Key Changes
-
medium
Benitec Biopharma executed an engagement letter with Ernst & Young LLP on September 29, 2026, appointing EY as its independent registered public accounting firm for the fiscal year ending June 30, 2027.
Item 4.01 verify on EDGAR →
Summary
Benitec Biopharma Inc. has engaged Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending June 30, 2027. The engagement letter was executed on September 29, 2026, following EY's completion of its client acceptance process.
The filing does not disclose any disagreements or reportable events with the prior auditor, indicating a routine auditor transition. For retail investors, this is a standard governance update with no immediate financial impact.
Section-by-Section Diff
Event · Item 4.01 — Changes in Registrant's Certifying Accountant
Item 4.01 — Changes in Registrant's Certifying Accountant filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On September 29, 2026, the Company and EY executed an engagement letter to engage EY as the Company’s independent registered public accounting firm.
The company formally engaged Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending June 30, 2027. This follows EY's completion of its client acceptance process on September 28, 2026. The filing does not disclose any disagreements or reportable events with the prior auditor.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 30, 2026 · How we verify